Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322179 · ClinicalTrials.gov registry record
Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C
A clinical trial, sponsored by Palo Alto Veterans Institute for Research.
- Completed
- Registry status
- 22
- Enrollment target
NCT00322179: Completed study, sponsored by Palo Alto Veterans Institute for Research.
NCT00322179 is a clinical trial that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322179 has completed, sponsored by Palo Alto Veterans Institute for Research.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in obese patients. Alterated immune response had been reported in obese patients. The goal of current study is to determine the immune response to interferon in obese compared to non-obese chronic hepatitis C in an tissue culture system.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-11 |
What the finished NCT00322179 record still lists
NCT00322179 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00322179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00322179 about?
NCT00322179 is a clinical study titled "Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C". The response rate to interferon-based anti-viral therapy for chronic hepatitis C is lower in patients who are obese. However, it is not clear whether this is related to suboptimal dosing of the medication or alterated response in obese patients. Alterated immune response had been reported in obese p...
What is the current status of trial NCT00322179?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2005-11. Estimated completion is 2008-11.
Who is sponsoring clinical trial NCT00322179?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia